LOGIN
ID
PW
MemberShip
2025-07-12 15:28
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
InterView
¡®Reimbursing Revlimid as maintenance therapy beneficial¡¯
by
Eo, Yun-Ho
Mar 16, 2023 05:45am
The multiple myeloma treatment ¡®Revlimid¡¯ has finally been listed for reimbursement after 4 long years of await as maintenance therapy, starting from the new year of 2023. Reimbursement of Revlimid as maintenance therapy had undergone various twists and turns in Korea. Since 2019, BMS Korea had actively sought to list the drug for reimb
InterView
SGLT-2 I is a great help in the treatment of heart failure
by
Kim, Jin-Gu
Feb 6, 2023 05:51am
SGLT-2 inhibitors developed for the purpose of treating diabetes are speeding up the expansion into the area due to heart failure. The use of SGLT-2 inhibitors targeting heart failure is expanding not only in university hospitals but also in the local area. This trend has been expanding since the revision of the domestic heart failure guid
InterView
Takeda will lead industry with focus on Oncology
by
Eo, Yun-Ho
Feb 2, 2023 05:47am
A company has achieved evolution through aggressive investment in line with the current trend. Through such evolution, Takeda Pharmaceuticals has become renowned as a 'Big Pharma' rather than a 'Japanese company' from some point. The company had previously focused on OTCs and chronic diseases such as diabetes and hypertension. However, th
InterView
¡°Novartis will lead the provision of innovative medicines¡±
by
Eo, Yun-Ho
Jan 25, 2023 06:08am
The Korean subsidiary of Novartis underwent a period of turmoil last year. The company integrated its Pharmaceuticals and Oncology business units in line with the reorganization policy set by its global headquarters. Before then, the company had been operating 2 separate business units independently under one name. The two units had separ
InterView
Avodart, Real World Data
by
Dec 28, 2022 05:48am
GSK's large-scale real-world clinical results of Avodart, a treatment for prostatic hypertrophy, which marks the 13th anniversary of its launch in Korea, have been released for the first time. Based on actual field data, the company expressed its ambition to further strengthen Avodart's position in early hair loss treatment.LEAD clinical trials
InterView
IL-23 Continued research on inflammatory pathways
by
Dec 23, 2022 06:05am
Efforts to develop treatments through various studies such as combination therapy and receptor targets. Interleukin (IL) inhibitors used in autoimmune diseases such as psoriasis are evolving as several companies continue to develop them. With the emergence of more effective treatments, psoriasis can expect "PASI 100," which means complete improv
InterView
From domestic sales to the global brand general
by
Dec 22, 2022 05:53am
Considering healthcare systems around the world such as in Russia, the Middle East, Southeast Asia, and South America, the company will set up a strategy to launch a new anti-cancer drug. It is the main job of Kim Soo-yeon (48), executive director of the International Lung Cancer Brand, at AstraZeneca. Managing director Kim's role has also grown
InterView
The issue of SE of JAK inhibitors should be given authority
by
Kim, Jin-Gu
Dec 2, 2022 06:08am
The treatment results of rheumatoid arthritis have improved dramatically. This is because doctors can use it a lot. Following the advent of MTX in the late 1980s, TNF-alpha inhibitors changed the treatment paradigm of this disease. Recently, JAK inhibitors that improved the shortcomings of TNF-alpha inhibitors have emerged. JAK inhibitors, wh
InterView
The key to treating stroke tx is preventing the recurrence
by
Kim, Jin-Gu
Nov 23, 2022 06:04am
Stroke is a battle against time. Whether the blood vessels in the brain are blocked (brain infarction) or burst (brain hemorrhage), blood should be supplied to the brain normally within a short period of time. The medical community explains that the golden time of stroke is 4.5 hours. This means that the problem can be solved only when the sy
InterView
¡°Korea is fully capable of developing new microbiome drugs"
by
Nho, Byung Chul
Nov 18, 2022 06:04am
¡°The development of metagenomics technology that extracts DNA directly from samples without culturing in 1998 enabled the field of human microbiome research to make a giant leap forward. The success and failure of innovative new microbiome-based therapeutics depend on identifying, standardizing, and materializing the keystone species in the
1
2
3
4
5
6
7
8
9
10
>